Clinical trials: T-Cell Chronic Lymphocytic Leukemia
Leukemia, Lymphoma
DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma
This is a phase I dose escalation study of DT2219ARL for the treatment of relapsed or refractory B-lineage leukemia and lymphoma. Patients will receive a single course of DT2219ARL as a 4 hour infusion on days 1, 3, 5, and 8.
- Trial name
- NCT00889408
- Testing
- DT2219ARL
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
B Cell Leukemia, B Cell Lymphoma
A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma
Autologous T cells engineered to express chimeric antigen receptors (CARs) against leukemia antigens such as CD19 on B cells have shown promising results for the treatment of relapsed or refractory B-cell malignancies.
- Trial name
- NCT03166878
- Testing
- UCART019
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chinese PLA General Hospital
Chronic Myeloproliferative Disorders, Kidney Cancer
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant using stem cells that closely match the patient's stem cells, helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00295997
- Testing
- anti-thymocyte globulin, filgrastim, graft-versus-tumor induction therapy
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- University of California, San Francisco
Diffuse Large B Cell Lymphoma, Burkitt Lymphoma
Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma
This is a single-center, open-label and pragmatic clinical trial to evaluate the primary efficacy and safety of anti-CD19 chimeric antigen receptor (CAR)-modified T cells (CART-CD19) with concurrent BTK inhibitor in patients with…
- Conditions
- Diffuse Large B Cell Lymphoma, Burkitt Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT05020392
- Testing
- BTK inhibitor+ Fludarabine-based chemotherapy + CAR-T-CD19 Cells, Fludarabine-based chemotherapy + CAR-T-CD19 Cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Cytokine Release Syndrome, Immune Effector Cell-Associated Neurotoxicity Syndrome
RPM Signals in Outpatient CAR T Therapy
The goal of this observational study is to learn how patients' vital signs and symptoms change during outpatient CAR T-cell therapy with lisocabtagene maraleucel (liso-cel), a type of cancer treatment.
- Conditions
- Cytokine Release Syndrome, Immune Effector Cell-Associated Neurotoxicity Syndrome, B-Cell Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT07882732
- Volunteers
- 125 people
- Sponsor
- Current Health
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML)
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
Patients less than or equal to 21 years old with high-risk hematologic malignancies who would likely benefit from allogeneic hematopoietic cell transplantation (HCT).
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), NK-Cell Leukemia
- Trial name
- NCT03849651
- Testing
- Cyclophosphamide, Fludarabine, Thiotepa
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- St. Jude Children's Research Hospital
B Cell Leukemia
A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia
Allogenic hematopoietic stem cell transplant (Allo-HSCT) is routinely used for treatment of aggressive hematological malignancies.
- Trial name
- NCT03463928
- Testing
- donor-derived CD19/22 bispecific CAR-T cells or CD19-directed CAR-T cells; donor-derived-HSCT
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Chinese PLA General Hospital
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
This phase II trial studies how well cyclophosphamide works in preventing chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant in patients with hematological malignancies.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT01427881
- Testing
- cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Fred Hutchinson Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer
This phase II trial studies how well tacrolimus and mycophenolate mofetil works in preventing graft-versus-host disease in patients who have undergone total-body irradiation (TBI) with or without fludarabine phosphate followed by…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00089011
- Testing
- fludarabine phosphate, total-body irradiation, mycophenolate mofetil
- Where
- 5 sites in United States, Italy
- Volunteers
- 150 people
- Sponsor
- Fred Hutchinson Cancer Center
CHRONIC LYMPHOCYTIC B-LEUKEMIA
Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells
In the laboratory, we will put a special gene into cancer cells that have been taken from the subject. This gene will make the cells produce interleukin 2 (IL-2), which may help the patient's immune system kill cancer cells.
- Trial name
- CLONTAK (NCT00224354)
- Testing
- IL-2 secreting and hCL4OL-expressing autologous B-CLL cells, IL-2, CD40L
- Sponsor
- Baylor College of Medicine
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Basophilic Leukemia
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders
This phase I trial is studying the side effects and best dose of vorinostat when given together with cytarabine and etoposide in treating patients with relapsed or refractory acute leukemia or myelodysplastic syndromes or…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7)
- Trial name
- NCT00357305
- Testing
- vorinostat, cytarabine, etoposide
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Bone Marrow Suppression, Fever, Sweats, and Hot Flashes
Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count
RATIONALE: Antibiotic therapy may prevent the development of infection in patients with hematologic cancer and the persistent fever caused by a low white blood cell count.
- Conditions
- Bone Marrow Suppression, Fever, Sweats, and Hot Flashes, Infection, Leukemia
- Trial name
- NCT00003805
- Testing
- piperacillin sodium, piperacillin-tazobactam, tazobactam sodium
- Where
- 28 sites in United States, Belgium and 11 more
- Volunteers
- 859 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia
Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia
Non-Hodgkin CD20 + Indolent Lymphoma (iNHL) and Chronic Lymphatic Leukemia (CLL) are the most frequent neoplasms of B lymphocytes.
- Trial name
- BET2017 (NCT03823365)
- Testing
- Blinatumomab Expanded T-cells (BET)
- Where
- Italy
- Volunteers
- 19 people
- Sponsor
- A.O. Ospedale Papa Giovanni XXIII
Cachexia, Lymphoma
Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer
RATIONALE: Nutritional supplements may help prevent loss of appetite, weight loss, and fatigue in patients with advanced cancer.
- Conditions
- Cachexia, Lymphoma, Lymphoproliferative Disorder, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00053053
- Testing
- Juven, Non-Juven Supplement
- Where
- 250 sites in United States, Canada
- Volunteers
- 472 people
- Sponsor
- Radiation Therapy Oncology Group
Leukemia, B-Cell, Lymphoma, B-Cell
Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies
This single arm, open-label, multi-center clinical trial is studying CD19 targeted chimeric antigen receptor T cells therapy in treating patients with CD19 positive malignant B-cell derived leukemia and lymphoma that is relapsed…
- Trial name
- NCT02813837
- Testing
- CD19CART
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Innovative Cellular Therapeutics Co., Ltd.
Lymphoblastic Leukemia, Relapsed or Refractory Multiple Myeloma (RRMM)
Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
This is an open label, single-site, dose-escalation study in up to 18 participants with Relapsed or Refractory Multiple Myeloma, Acute B-Cell Leukemia, and B-Cell Lymphoma.
- Trial name
- ECAR01 (NCT06961669)
- Testing
- Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Anhui Provincial Hospital
Relapsed/Refractory B-cell Lymphomas, Diffuse Large B Cell Lymphoma (DLBCL)
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
CLBR001 + SWI019 is an combination investigational immunotherapy being evaluated as a potential treatment for patients diagnosed with B cell malignancies who are refractory or unresponsive to salvage therapy or who cannot be…
- Conditions
- Relapsed/Refractory B-cell Lymphomas, Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL)
- Trial name
- NCT04450069
- Testing
- CLBR001 and SWI019
- Where
- 8 sites in United States
- Volunteers
- 18 people
- Sponsor
- Calibr, a division of Scripps Research
Lymphoma, Small Intestine Cancer
CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy
RATIONALE: CC-5013 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have solid tumors and/or lymphoma that did not respond to…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00031941
- Testing
- lenalidomide
- Where
- 2 sites in United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Leukemia, Lymphoma
AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders
RATIONALE: Giving chemotherapy with or without total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00547196
- Testing
- filgrastim, Busulfan, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
Leukemia, Lymphoma
T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer
RATIONALE: Giving chemotherapy, such as fludarabine and cyclophosphamide, and total-body irradiation before a donor umbilical cord blood transplant helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm
- Trial name
- NCT00602693
- Testing
- umbilical cord blood transplantation, Allopurinol, fludarabine phosphate
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Masonic Cancer Center, University of Minnesota